AMWatch

"We are not stopping everything because of the virus": DNB has biotech fund launch on the horizon

In fact, a biotech fund might be a timely addition given the pandemic crisis we are currently facing, DNB Asset Management's Head of Equities says to AMWatch.

Photo: Colourbox

DNB Asset Management will expand its fund offering even further this spring after the launch of its multi-asset fund and three equity funds. The next strategy in the pipeline is a biotech fund.

"We are not stopping everything because of the virus – in fact a biotech fund might be a timely addition given the pandemic crisis we are currently facing," Knut Hellandsvik, head of equities at DNB Asset Management, explains.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

Nasdaq reports record year in Europe

In 2021, the number of new equity listings on the Nasdaq exchange in Copenhagen broke the old record set in 2007, and in Stockholm, the exchange recorded its highest-ever number of new listings. Nasdaq also had increasing trading volumes last year.

Further reading

Related articles

Latest news

Jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch